Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
Completed
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Registration Number
- NCT02547532
- Lead Sponsor
- Fondazione Salvatore Maugeri
- Brief Summary
In the context of the increasing evidence of the pathogenetic role of microbiome in COPD, our aim is to determine the total and specific bacterial and viral load in sputa from patients with COPD due to AATD and to correlate these findings with cellular, biochemical and immunological characteristics of sputa. These quantitative data obtained from sputum will be analyzed in the context of the clinical and physiological parameters of the patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- diagnosis of COPD and a clinical stable condition, i.e. at least three months from the last AECOPD and/or antibiotic treatment.
For patients with AATD this condition will be diagnosed by laboratory tests showing low levels of AAT and genotyping of AATD-related genes.
.
Exclusion Criteria
- The presence of important co-morbidities (diabetes, systemic or organ infections, immunodeficiency, tumors, moderate-severe heart failure) will be considered as exclusion criteria.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method composition of microbioma in sputa 2 years
- Secondary Outcome Measures
Name Time Method correlation with clinical and physiological parameters 2 years